Session » Vasculitis Poster I

Date: Sunday, November 8, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 885

a Retrospective Analysis of Low Dose Cyclophosphamide Therapy in Systemic Vasculitides

9:00AM-11:00AM: Abstract Number: 865

Abdominal Visceral Adipose Tissue Measured By Dual Energy X-Ray Absorptiometry (DXA) As a Novel Surrogate Marker of Cardiovascular Risk in Primary Necrotizing Vasculitides

9:00AM-11:00AM: Abstract Number: 881

ANCA Associated Vasculitis with Hypocomplementemia Has More Diffuse Alveolar Hemorrhage and a Poor Prognosis

9:00AM-11:00AM: Abstract Number: 861

ANCA-Associated Pauci-Immune Glomerulonephritis: ¿Always Pauci-Immune?

9:00AM-11:00AM: Abstract Number: 890

Anti-IgE Monoclonal Antibody in Refractory and/or Relapsing Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss): Data from 17 Patients

9:00AM-11:00AM: Abstract Number: 864

Anticytokine Autoantibody Profiling in Five Types of Systemic Vasculitis

9:00AM-11:00AM: Abstract Number: 892

Autoimmune Associated Orbital Inflammatory Masses and Response to Immunosuppressive Therapy

9:00AM-11:00AM: Abstract Number: 889

Central Nervous System Involvement of Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss): Retrospective Analysis of 26 Cases and Review of the Literature

9:00AM-11:00AM: Abstract Number: 871

Clinicians’ Perspective on Aspects of ANCA-Associated Vasculitis That Influence Patients’ Function and General Health: A Delphi Exercise Based on the International Classification of Function, Disability and Health

9:00AM-11:00AM: Abstract Number: 863

Contribution of MPO-/PR3-ANCA Tests to the Diagnosis of ANCA-Associated Vasculitis in a Community Hospital: Evaluation of 2,782 Samples

9:00AM-11:00AM: Abstract Number: 876

Damage Develops Early and Is Common in Children with Chronic Systemic Vasculitis

9:00AM-11:00AM: Abstract Number: 870

Development of an Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Patient-Reported Outcome Measure: Identification of Salient Themes and Candidate Questionnaire Item Development

9:00AM-11:00AM: Abstract Number: 875

Differences in Early Damage Patterns in Various Forms of Primary Systemic Vasculitis

9:00AM-11:00AM: Abstract Number: 879

Diffuse Alveolar Hemorrhage Secondary to ANCA-Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes

9:00AM-11:00AM: Abstract Number: 862

Discriminative Performance of Nasal Endoscopic Findings and History Items in Patients with Granulomatosis with Polyangiitis

9:00AM-11:00AM: Abstract Number: 856

Elderly Versus Younger Patients with ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 893

Epidemiological Features of Childhood IgA Vasculitis (Henoch-Schönlein) in a French County: A Population-Based Survey

9:00AM-11:00AM: Abstract Number: 853

Evaluation and Validation of Case-Finding Algorithms for the Identification of Patients with Granulomatosis with Polyangiitis in Large Healthcare Administrative Databases

9:00AM-11:00AM: Abstract Number: 883

Evaluation of Thiopurine Metabolites Monitoring in Patients Treated with Azathioprine for Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 880

Extra-Corporeal Membrane Oxygenation and Diffuse Alveolar Haemorrhage: A Single Centre Case Series and Analysis of the ELSO Database

9:00AM-11:00AM: Abstract Number: 866

High Rate and Bimodal Pattern of Severe Infection in a Selected ANCA Associated Vasculitis Cohort

9:00AM-11:00AM: Abstract Number: 877

Improved Survival in Granulomatosis with Polyangiitis: A Population-Based Study

9:00AM-11:00AM: Abstract Number: 887

Intravenous Immunoglobulin As Immunomodulating Agent in ANCA-Associated Vasculitides: A French Nationwide Study of 92 Patients

9:00AM-11:00AM: Abstract Number: 894

Late-Onset IgA Vasculitis in Adult Patients Exhibits Distinct Clinical Characteristics and Outcomes

9:00AM-11:00AM: Abstract Number: 891

Long-Term Use of Rituximab for Eosinophilic Granulomatosis with Polyangiitis

9:00AM-11:00AM: Abstract Number: 882

Lung Damage in ANCA Associated Vasculitis Assessed By Vasculitis Damage Index: Recurrent Pulmonary Infections Have a Significant Contribution

9:00AM-11:00AM: Abstract Number: 869

Lymphoma in Patients with Granulomatosis with Polyangiitis

9:00AM-11:00AM: Abstract Number: 854

Nationwide Incidence of Anti Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis in Iceland

9:00AM-11:00AM: Abstract Number: 860

Neutrophil/Lymphocyte Ratio: Could It be a Prognostic Indicator for Renal Outcome in Patients with Granulomatosis with Polyangiitis?

9:00AM-11:00AM: Abstract Number: 884

Patient Perceptions of Treatment with Glucocorticoids in ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 888

Plasma Exchanges to Treat Primary Systemic Necrotizing Vasculitides: Data from a French Nationwide Study

9:00AM-11:00AM: Abstract Number: 859

Predictors of Renal Histopathology in Antineutrophil Cytoplasmic Antibody Associated Glomerulonephritis

9:00AM-11:00AM: Abstract Number: 857

Prognosis Value of Geriatric Assessment Scales in Older Adults with New Onset ANCA-Associated Vasculitis: A Pilot Retrospective Study

9:00AM-11:00AM: Abstract Number: 895

Relapses and Predictive Factors in Henoch-SchÖnlein Purpura. study of 417 Patients

9:00AM-11:00AM: Abstract Number: 868

Risk Factors for Cytomegalovirus Reactivation in Patients with Antineutrophil Cytoplasmic Antibody -Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 886

Rituximab As a Cyclophosphimide Sparing Agent for Patients with Multi-Relapsing Antineutrophil Cytoplasmic Antibody Associated Small Vessel Vasculitis

9:00AM-11:00AM: Abstract Number: 855

Seasonality in ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 878

Significance of Interstitial Pneumonitis in Microscopic Polyangiitis

9:00AM-11:00AM: Abstract Number: 867

Simultaneous Measurement of 25-Hydroxyvitamin D and Procalcitonin in Granulomatosis with Polyangiitis (GPA): Differentiation of Activity from Infection?

9:00AM-11:00AM: Abstract Number: 858

Stimulated Renal Glomerular Endothelial Cells Were Damaged By Fiber-like NETs Released By Neutrophils in ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 873

The ANCA-Vasculitis Index of Damage (AVID): Performance of a New Damage Instrument

9:00AM-11:00AM: Abstract Number: 874

The Short Term Damage Burden in Vasculitis and Vasculitis Mimics As Measured By the Vasculitis Damage Index

9:00AM-11:00AM: Abstract Number: 872

Work Limitations and Disability in Patients with Systemic Vasculitis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].